Has The New Economy Been Chasing Its Tail?
Stephen Roach, Morgan Stanley's chief economist, is convinced that the
reason for the 2001 stock market crunch is not just the collapse of the techology
sector, but also overreliance on technology in other businesses.
Roach argues that companies overinflated their information technology budgets
in the past two years as a result of widespread fears of Y2K bugs. Roach argues
that the capital outlays that came to 9 percent in the fourth quarter of 1999
should not have been raised to 21 percent in the first quarter of 2000. His
essential point is that increases such as this, in a field where machines become
rapidly obsolete, are unsustainable. The benefits of technological upgrades
do not offset the costs.
Furthermore, in an environment where the stigma of a company profit warning
is eroding through sheer prevalence, a decrease in technology spending is going
to create ripples, according to Roach. In the 1990s, productivity growth more
than doubled to an annual average growth rate of 2.4 percent, and even Alan
Greenspan attributes part of the boom to the manufacture of IT equipment. With
CEOs slashing technology budgets, there is a risk of creating a feedback loop,
where lower demand for computers depresses overall productivity growth. Lower
productivity hurts the overall economy, companies make less money, they have
less to spend on IT, and the cycle continues.
Despite a gloomy forecast, it is unclear if this pattern will materialize.
It hinges on the theory that the use of IT does not generate sufficient new
capability and efficiency to justify the cost. This is a difficult question
to answer, considering that_the debate still goes on over whether a simple washing
machine actually saves more time than hand washing. A survey by PricewaterhouseCoopers
found that Internet-savvy companies increased productivity 13.4 percent compared
with 4.9 percent of those that didn't. And although IT budgets have rolled
back from the crest of 31.4 percent, year-end spending was still 10.7 percent,
indicating that CEOs haven't given up the faith.
From Anna Bernasek, "Buried In Tech," Fortune, April 16,
2001, pp. 51-52.
Health Benefit Plans Need Rehab
Is it worthwhile for employers to provide employee benefits to help their workers
deal with substance abuse issues? In a time when overall expenditures on mental
health and substance abuse lag behind overall health care, and when more and
more of that particular burden is being shifted onto the taxpayer, employers
should bear in mind several facts when making health care decisions.
Substance abuse is a chronic condition. A round of treatment is unlikely
to effect a permanent cure, and expecting such a result is unreasonable. Long-term
remission is a much more practical goal, especially in view of the fact that
people treated for diabetes, hypertension, or asthma relapse more frequently
than substance abusers.
Substance abuse is not somebody else's problem. Substance abuse
is not limited to the poor and unemployed — studies show that in 1991, 54
percent of cocaine users had full-time jobs, and by 1995 that figure rose to
65 percent.
Abuse treatments are extremely cost effective. A 1994 study showed that
the health care claims that arose from a substance abuse problem were about
$550 per month greater than if the same person had received treatment for the
underlying cause. An untreated substance abuse problem can also increase other
costs. Dependent medical and mental health benefits, worker's compensation
and disability claims, and losses incurred by decreases in worker attendance,
productivity, and product quality all can arise from ongoing substance abuse.
State programs have shown savings of $6 to $7 in medical, legal, and welfare
costs for every dollar spent on abuse treatment. Nor is it practical to simply
fire an abuser because of an addiction — in the current labor market, estimates
range that it costs companies anywhere from $10,000 to two years' salary
to replace lost employees and all their skills.
Benefit programs are often under attack from other sources. _ith the
recent scrutiny of managed care plans, it should come as no surprise that HMOs
are quite eager to buy into the myths and misconceptions to place barriers between
costly therapy and those who need it. Managed care makes money by reducing the
level and amount of treatment, which can be crippling to any serious treatment
of chronic disease. Treatment centers are in fact scaling back the level of
service they provide because they know so much of what they offer is unlikely
to be approved by HMOs.
From Jeffrey C. Merrill, MD, "Substance Abuse: Myths and Realities
in the Corporate Sector," Business & Health, January 2001, pp.
31-36.